Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerindocianine for ureter delineation
NCT04636567Phase 2Withdrawn
- Sponsor
- LI-COR Biosciences
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nerindocianine in ureter injury, sponsored by LI-COR Biosciences. Primary endpoint: Evaluation of ureter delineation using a Likert scale. Planned start Mar 2021; status: withdrawn.
02
Drugs
nerindocianine
03
Conditions
ureter injury
Beyond the preview
Go deeper on NCT04636567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636567.